SEC Tracker
Get the app

AbbVie ABBV

AbbVie reports Q3 2026 results

Form
8-K
Filed
Importance
Routine
  1. Acquired IPR&D and milestones expense of $216M in Q3 2026
  2. GAAP and non-GAAP EPS impacted by $0.11 each
  3. Full-year 2026 adjusted EPS guidance: $13.76 - $13.96
  4. Q3 2026 adjusted EPS guidance: $3.73 - $3.77

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when AbbVie files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float over $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Johnson & Johnson JNJ public float $367.0B, Jun 29, 2025
  2. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  3. Merck MRK public float $198.1B, Jun 30, 2025
  4. Pfizer PFE public float $138.0B, Jun 29, 2025
  5. Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025